VHL
Reactivity: Human
IHC, ELISA
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Titration of the VHL antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,IHC (Paraffin): 1:50-1:100,Flow Cytometry: 1:10-1:50
Restrictions
For Research Use only
Format
Liquid
Buffer
In 1X PBS, pH 7.4, with 0.09 % sodium azide
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
Aliquot the VHL antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.
Target
VHL
(Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.